The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives

ABSTRACT Introduction Somatostatin analogs (SSAs) were developed as antisecretory agents to palliate hormonal symptoms in patients with functioning neuroendocrine tumors (NETs). Their antiproliferative activity has been established in the phase 3 PROMID and CLARINET trials. SSAs currently represent the standard first-line therapy for the majority of well-differentiated G1/G2 gastroenteropancreatic NETs as well as for pulmonary NETs. Areas covered An update on the clinical applications of established SSAs for the treatment of NETs is provided. Perspectives on emerging nonpeptide SSAs such as paltusotine and innovative formulations of octreotide (CAM2029) are included. Expert opinion SSAs represent the cornerstone of treatment for both functioning and nonfunctioning NETs. While standard-dose SSAs have a defined place in the therapeutic algorithm of well-differentiated NETs, uncertainties remain on how to best integrate above-label doses of SSAs in the treatment sequence, particularly when tumor control is the goal. Octreotide and lanreotide appear to be clinically interchangeable, and no signs of superiority of one agent over the other has been observed so far. Whether SSAs may be exploited in the maintenance setting following more aggressive treatments, whether continuing SSAs beyond-progression after first-line therapy could be an effective treatment strategy, and whether new-generation SSAs such as pasireotide could overcome resistance to established SSAs are key areas of investigation.

• Publication year

  2024

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2024-10-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14737175.2024.2417419PMID 39415322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

  2024cited by this paper
• Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis

  2024cited by this paper
• Somatostatin receptors and the associated intracellular machinery: the two sides of the coin.

  2024cited by this paper
• [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

  2024cited by this paper
• Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

  2024cited by this paper
• Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

  2024cited by this paper
• Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

  2024cited by this paper
• Is NETTER-2 a practice-changing trial?

  2024cited by this paper
• Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review

  2024cited by this paper
• European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes

  2023influential reference
• Resistance of neuroendocrine tumours to somatostatin analogs

  2023cited by this paper
• Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?

  2023cited by this paper
• AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.

  2023cited by this paper
• Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

  2023cited by this paper
• Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist

  2022cited by this paper
• PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

  2022influential reference
• Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

  2022cited by this paper
• Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

  2022cited by this paper
• European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

  2022cited by this paper
• Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors

  2022cited by this paper
• Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis

  2022cited by this paper
• High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?

  2022cited by this paper
• Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature

  2022cited by this paper
• Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms

  2022cited by this paper
• Role of Somatostatin Signalling in Neuroendocrine Tumours

  2022cited by this paper
• 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

  2021cited by this paper
• Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.

  2021cited by this paper
• Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2021cited by this paper
• External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

  2021influential reference
• In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

  2021cited by this paper
• Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit

  2020cited by this paper
• Somatostatin analogs (SSA) improve respiratory symptoms in patients with diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH).

  2020cited by this paper
• METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

  2020cited by this paper
• Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs.

  2020cited by this paper
• Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors

  2020cited by this paper
• Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours

  2020cited by this paper
• Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cited by this paper
• Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

  2020cited by this paper
• Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

  2020influential reference
• Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort

  2020cited by this paper
• Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%?

  2020influential reference
• Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial

  2019cited by this paper
• Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor.

  2019cited by this paper
• Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.

  2019cited by this paper
• A prospective study of the pathophysiology of carcinoid crisis

  2019cited by this paper
• Management of carcinoid syndrome: a systematic review and meta-analysis.

  2019cited by this paper
• Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

  2019cited by this paper
• Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study.

  2019cited by this paper
• Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?

  2018cited by this paper
• Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

  2018cited by this paper
• Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.

  2018cited by this paper
• Paraneoplastic Cushing syndrome, case-series and review of the literature

  2018cited by this paper
• Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

  2018cited by this paper
• Incidence and Prognostic Significance of Carcinoid Lymph Node Metastases.

  2018cited by this paper
• Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study

  2018cited by this paper
• The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy

  2018cited by this paper
• Gastroenteropancreatic Neuroendocrine Tumors

  2018influential reference
• Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

  2017influential reference
• Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

  2017influential reference
• Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

  2017cited by this paper
• Outcome Analysis of First‐line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG‐PET/CT

  2017cited by this paper
• Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

  2017cited by this paper
• Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

  2017cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

  2016cited by this paper
• Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

  2016cited by this paper
• Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

  2016cited by this paper
• AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas

  2016cited by this paper
• Bronchopulmonary Carcinoids causing Cushing Syndrome: Results from a Multicentric Study Suggesting a More Aggressive Behavior

  2015cited by this paper
• Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers

  2015cited by this paper
• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

  2015cited by this paper
• The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors

  2015influential reference
• Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.

  2015cited by this paper
• Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors.

  2015cited by this paper
• Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

  2015cited by this paper
• Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End Results (SEER) database review of demographics and survival in 187,991 cases.

  2015cited by this paper
• Prognostic Validity of the American Joint Committee on Cancer Staging Classification for Midgut Neuroendocrine Tumors

  2014cited by this paper
• Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

  2014cited by this paper
• Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

  2014cited by this paper
• Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

  2014influential reference
• Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

  2014cited by this paper
• Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

  2013cited by this paper
• Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.

  2013cited by this paper
• Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients

  2013cited by this paper
• Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

  2012cited by this paper
• GPCR mediated regulation of synaptic transmission.

  2012cited by this paper
• Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Long‐term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)

  2011cited by this paper
• Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

  2010cited by this paper
• The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum

  2010cited by this paper
• Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

  2010cited by this paper
• Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients.

  2009cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

  2009cited by this paper
• Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR

  2009cited by this paper

• Individualized treatment strategies for primary hepatic neuroendocrine carcinoma: Two case reports and literature review (A CARE-compliant case report)

  2026cites this paper
• Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future.

  2025cites this paper
• Pulmonary Carcinoids: Diagnostic and Therapeutic Approach

  2025cites this paper
• Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors

  2025cites this paper
• Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy

  2025cites this paper